Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 10, 2012, Pages

  D'Amico, M ^a   Mejias M ^a   Garcia Pras E ^a   Abraldes, J G ^a   Garcia Pagan J C ^a   Fernandez M ^a   Bosch, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Angiogenesis; Liver cirrhosis; Portal pressure

Indexed keywords

PROPRANOLOL; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DRUG EFFECT; FEEDING; HEMODYNAMICS; LIVER CIRRHOSIS; LIVER FIBROSIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; TREATMENT DURATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZENESULFONATES; DRUG THERAPY, COMBINATION; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PROPRANOLOL; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84861163983     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00252.2011     Document Type: Article

References (36)

1. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 290: G980-G987, 2006.
2. Abraldes JG, Pasarin M, Garcia-Pagan JC. Animal models of portal hypertension. World J Gastroenterol 12: 6577-6584, 2006.
3. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37: 902-908, 2003.
4. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115: 209-218, 2005.
5. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 48, Suppl 1: S68-S92, 2008.
6. Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, Maimone S, Pleguezuelo M, Xirouchakis I, Guerrini GP, Patch D, Yu D, O'Beirne J, Dhillon AP. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49: 1236-1244, 2009.
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395, 2000.
8. Casado M, Bosch J, Garcia-Pagan JC, Bru C, Banares R, Bandi JC, Escorsell A, Rodríguez-Láiz JM, Gilabert R, Feu F, Schorlemer C, Echenagusia A, Rodés J. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114: 1296-1303, 1998.
9. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 131: 1611-1624, 2006.
10. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53: 762-768, 2010.
11. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and plateletderived growth factor blockade in rats. Hepatology 46: 1208-1217, 2007.
12. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 50: 604-620, 2009.
13. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126: 886-894, 2004.
14. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodés J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346: 1056-1059, 1995.
15. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 87: 1153-1155, 1996.
16. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, Bosch J; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 362: 2370-2379, 2010.
17. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 362: 823-832, 2010.
18. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353: 2254-2261, 2005.
19. Groszmann RJ, Kravetz D, Bosch J, Glickman M, Bruix J, Bredfeldt J, Conn HO, Rodes J, Storer EH. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 2: 757-762, 1982.
20. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 157: 258-270, 2009.
21. Hernandez-Guerra M, Garcia-Pagan JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol 39, Suppl 2: S131-S137, 2005.
22. Huang YT, Lin HC, Tsai JF, Hou MC, Hong CY. Chronic administration of propranolol improves vascular contractile responsiveness in portal hypertensive rats. Eur J Clin Invest 27: 550-555, 1997.
23. Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 53: 200-208, 2010.
24. Leaute-Labreze C, Dumas de la RE, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 358: 2649-2651, 2008.
25. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 45: 817-825, 2007.
26. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
27. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 39: 1185-1195, 2004.
28. Mejias M, Garcia-Pras E, Gallego J, Mendez R, Bosch J, Fernandez M. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. J Hepatol 52: 529-539, 2010.
29. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49: 1245-1256, 2009.
30. Pateron D, Tazi KA, Sogni P, Heller J, Chagneau C, Poirel O, Philippe M, Moreau R, Lebrec D. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 119: 196-200, 2000.
31. Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, Peck-Radosavljevic M. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 51: 865-873, 2009.
32. Semela D, Das A, Langer D, Kang N, Leof E, Shah V. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 135: 671-679, 2008.
33. Tazi KA, Barriere E, Moreau R, Heller J, Sogni P, Pateron D, Poirel P, Lebrec D. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 122: 1869-1877, 2002.
34. Thabout D, Shah VH. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 53: 976-980, 2010.
35. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, Carmeliet P, Jiménez W, Morales-Ruiz M. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46: 1919-1926, 2007.
36. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.